

Clinically Meaningful BP Reduction Across 7,000 Patients*^{1,2}

Medtronic Renal Denervation



The SPYRAL HTN Clinical Program features the **most rigorous and extensive patient experience** as shown in three randomized, sham-controlled trials, and the largest real-world patient study.³⁻⁶

REAL-WORLD PATIENT REGISTRY

GLOBAL SYMPPLICITY REGISTRY

16.7 ↓

mmHg Office SBP
at three years³

RANDOMIZED, SHAM-CONTROLLED TRIALS

SPYRAL HTN ON MED PILOT STUDY

9.4 ↓

mmHg Office SBP
at six months^{†4}

SPYRAL HTN OFF MED PIVOTAL TRIAL

9.2 ↓

mmHg Office SBP
at three months^{†**5}

GET DATA FIRST

*Patients enrolled in Medtronic-sponsored, funded or physician-initiated studies.

†RDN arm reduction from baseline.

**ANCOVA adjusted; secondary efficacy analysis.

1. Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *The Lancet*. 2002;360(9349):1903-1913.

2. Data on file, Medtronic. April 2021.


3. Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplixity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.

4. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *The Lancet*. 2018 Jun 9;391(10137):2346-2355.

5. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *The Lancet* 2020; Published online March 29, 2020. DOI:10.1016/S0140-6736(20)30554-7.

6. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *The Lancet*. 2017; 390:2160-2170.

H₂FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease

Vladimir Vasilev MD¹ | Dejana Popovic MD, PhD^{2,3}  | Gorica G. Ristic MD, PhD⁴ |
Ross Arena PhD⁵ | Goran Radunovic MD, PhD^{1,6} | Arsen Ristic MD, PhD^{1,2}

¹School of Medicine, University of Belgrade, Belgrade, Serbia

²Division of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia

³Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

⁴Department of Rheumatology and Clinical Immunology, Military Medical Academy and Medical Faculty of the Belgrade Defence University, Belgrade, Serbia

⁵Department of Physical Therapy, College of Applied Science, University of Illinois at Chicago, Chicago, Illinois, USA

⁶Institute of Rheumatology, Belgrade, Serbia

Correspondence

Dejana Popovic, Division of Cardiology, University Clinical Center of Serbia, Veljka Dugosevica 27g, Belgrade 11000, Serbia.
Email: dejanapopovic@yahoo.co.uk

Abstract

Background: Cardiovascular diseases are common cause of morbidity and mortality in patients with systemic connective tissue diseases (SCTD) due to accelerated atherosclerosis which couldn't be explained by traditional risk factors (CVDRF).

Hypothesis: We hypothesized that recently developed score predicting probability of heart failure with preserved ejection fraction (H₂FPEF), as well as a measure of right ventricular-pulmonary vasculature coupling [tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio], are predictive of atherosclerosis in SCTD.

Methods: 203 patients (178 females) diagnosed with SCTD underwent standard and stress-echocardiography (SE) with TAPSE/PASP and left ventricular (LV) diastolic filling pressure (E/e') measurements, carotid ultrasound and computed tomographic coronary angiography. Patients who were SE positive for ischemia underwent coronary angiography (34/203). The H₂FPEF score was calculated according to age, body mass index, presence of atrial fibrillation, ≥ 2 antihypertensives, E/e' and PASP.

Results: Mean LV ejection fraction was $66.3 \pm 7.1\%$. Atherosclerosis was present in 150/203 patients according to: 1) intima-media thickness > 0.9 mm; and 2) Agatstone score > 300 or Syntax score ≥ 1 . On binary logistic regression analysis, including CVDRF prevalence, echocardiographic parameters and H₂FPEF score, only H₂FPEF score remained significant for the prediction of atherosclerosis presence ($\chi^2 = 19.3$, HR 2.6, CI 1.5-4.3, $p < 0.001$), and resting TAPSE/PASP for the prediction of a SE positive for ischemia ($\chi^2 = 10.4$, HR 0.01, CI = 0.01-0.22, $p = 0.004$). On ROC analysis, the optimal threshold value for identifying patients with atherosclerosis was a H₂FPEF score ≥ 2 (Sn 60.4%, Sp 69.4%, area 0.67, SE = 0.05, $p < 0.001$).

Conclusions: H₂FPEF score and resting TAPSE/PASP demonstrated clinical value for an atherosclerosis diagnosis in patients diagnosed with SCTD.

KEYWORDS

coronary artery disease, H₂FPEF score, right ventricular-pulmonary vasculature uncoupling, systemic connective tissue disease

1 | INTRODUCTION

Cardiovascular diseases (CVD) are the most common cause of morbidity and mortality in patients with systemic connective tissue diseases (SCTD) generally due to premature atherosclerosis.¹ Current recommendations suggest assessment of general CVD risk factors (CVDRFs) in these patients, as part of risk prediction algorithms such as Systematic Coronary Risk Evaluation (SCORE)² and Framingham³ in order to calculate a 10-year risk of CVD events. These traditional risk factors include age, gender, blood pressure, smoking, diabetes mellitus, and hyperlipidemia and, according to calculated risk, preventive interventions are recommended.^{2,3} However, in SCTD, atherosclerosis cannot be explained by traditional CVDRF alone.^{1,4} They play a secondary role, while disease-specific factors can directly influence the cardiovascular system. Chronic systemic inflammation and autoimmunity interfere in a number of metabolic processes, generating a proatherogenic condition.^{1,4} In these patients, CVD is also influenced by anti-inflammatory therapy.^{1,4} Thus, the European League Against Rheumatism (EULAR) suggests screening, identification of CVDRF, and CVD risk management in all patients with SCTD.¹ The EULAR task force has advocated the use of a 1.5 multiplication factor for these risk prediction models when certain rheumatoid arthritis (RA) disease characteristics were present.¹ However, appropriate and validated SCTD-specific CVD risk prediction models are still lacking.¹ On the other hand, there is an urgent need to identify cardiovascular abnormalities early, before the development of irreversible damage.

It has been demonstrated that SCTDs are commonly associated with heart failure preserved ejection fraction (HFpEF) and pulmonary hypertension (PH),^{5,6} increasing the risk of death by almost twofold.⁷ The synergy amongst HFpEF, systemic inflammatory disorders and atherosclerosis represents a vicious circle leading to very poor survival.⁵ As systemic inflammation precedes the onset of HFpEF and atherosclerosis by years,⁸ it would be beneficial to conduct early risk prediction in order to prevent future adverse events.

We hypothesized that the recently developed H₂FPEF score, proposed to predict the probability of HFpEF through a composite score of six variables including age, body mass index (BMI), treatment with ≥ 2 antihypertensives, presence of atrial fibrillation, early diastolic filling pressure (E/e' ratio) and pulmonary artery systolic pressure (PASP) measured by echocardiography,⁹ is also predictive of atherosclerosis in patients diagnosed with SCTD. Moreover, we hypothesized that parameters of right ventricular-pulmonary vasculature coupling (RV-PV coupling) may also be predictive for atherosclerosis in this patient population. Thus, the purpose of the present investigation was to examine the predictive value of H₂FPEF score and tricuspid annular plane systolic excursion (TAPSE)/PASP ratio, as a measure of RV-PV coupling, for atherosclerosis presence in patients diagnosed with SCTD.

2 | METHODS

2.1 | Study cohort

From January 2018 to November 2019, 203 patients with SCTD (i.e., rheumatoid arthritis [RA], systemic lupus erythematosus [SLE],

systemic sclerosis [SSc], and Sjogren's syndrome [SS]) diagnosed according to current criteria¹⁰⁻¹⁷ were enrolled in this prospective observational study at the Clinical Center of Serbia. They were screened for study enrollment at the time of referral for a clinically indicated functional assessment. The study was approved by the local Ethical Institutional Review Board and informed consent was obtained from all subjects prior to enrollment. Clinical data from patients were collected during a preliminary visit, including age, gender, height, weight, BMI, and other CVDRFs (i.e., smoking status, hyperlipidemia, obesity, hypertension, heredity for CVD, diabetes mellitus). CVD risk was categorized as: (a) low; (b) intermediate; (c) high; and (d) very high according to SCORE value, determined using European Society of Cardiology (ESC) recommendations.² Subjects afterwards underwent a two dimensional (2-D) echocardiographic/Doppler evaluation, stress echocardiography (SE), computed tomographic coronary angiography (CTCA) and carotid ultrasound. Inclusion criteria were: (a) diagnosed RA, SLE, SSc, SS; (b) no previously documented CVD; (c) adequate echocardiographic windows; (d) left ventricular ejection fraction (LVEF) $\geq 50\%$; and (e) ability to exercise. Patients with normal LVEF and isolated tricuspid regurgitation due to a primary tricuspid valvular lesion were not included in the present investigation.¹⁸ Care was taken to identify the proper etiology of coexistent PH excluding idiopathic pulmonary arterial hypertension. Accordingly, we referred to Opatowsky et al.¹⁹ who proposed and validated 5-point prediction score based on the measurements of LV diastolic filling pressure (E/e'), the antero-posterior diameter of the left atrium and notching and/or shortened acceleration time of pulmonary flow. No subjects had significant right ventricular outflow tract obstruction.

2.2 | Echocardiography

Echocardiographic imaging was performed using a Philips IE33 and a 5.2-MHz transducer (Philips Medical Systems, Andover, MA) by two experienced cardiologists according to the current guidelines, at rest and during SE.^{20,21} A 2-D and Doppler examination was performed using a pre-specified echocardiographic protocol by views specifically designed to optimize RV imaging.²² B-mode echocardiography was performed to assess LVEF and left atrial volume (LAV) at rest. Early (E) and late (A) LV diastolic filling velocity were assessed at rest and during SE. Tissue Doppler imaging (TDI) was recorded at rest and during SE at end-expiration in the apical four chamber view at a sweep speed of 50 mm/s; the Doppler signal angle was less than 25%. Sample volume was positioned at 1 cm within the septal and lateral insertion sites of the mitral leaflets. Digitally stored loops of TDI were used for off-line calculations of myocardial velocities. Average values of LV lateral and septal annular early diastolic filling velocities (e') were used to calculate E/e'. The apical four-chamber view was used, and an M-mode cursor was placed through the lateral tricuspid annulus in real time to obtain TAPSE at rest and during SE. The brightness was adjusted off-line to maximize the contrast between the M-mode signal arising from the tricuspid annulus and the background. TAPSE was measured as the total displacement of the tricuspid annulus (millimeters) from end-diastole to end-systole, with values representing

TAPSE being averaged over three to five beats.²² PASP was estimated by Doppler echocardiography at rest and during SE from the systolic RV to right atrial pressure gradient using the modified Bernoulli equation. Right atrial pressure (assessed jugular venous pressure) was added to the calculated gradient to yield PASP. The TAPSE/PASP ratio, a measure of RV-PV coupling,²³ was calculated. Interobserver variability, assessed in a sample size of 20% of total population, was 3.5%, 3.4%, and 2.8% for M-mode, 2-D echocardiography and TDI, respectively.

2.3 | Stress echocardiography

All subjects performed SE on a treadmill using the Bruce protocol according to established guidelines.²⁴ Nitrates were stopped for 24 h, beta blockers for 3 days and calcium antagonists for 48 h before SE. Tea, coffee, cola-drinks, chocolate, and smoking were not allowed for 24 h before the evaluation. Standard 12-lead electrocardiograms were obtained after adequate skin preparation, at rest, each minute during exercise, and for at least 5 min during the recovery phase, according to established guidelines.²⁴ Blood pressure was measured using a standard cuff sphygmomanometer. Test termination criteria consisted of: (a) symptoms (i.e., dyspnea and/or fatigue); (b) sustained ventricular tachycardia (VT) and non-sustained VT that interfered with hemodynamic stability; (c) > 2 mm of horizontal or downsloping ST segment depression; (d) a drop of systolic blood pressure > 20 mm Hg during progressive exercise; (e) or reaching a submaximal heart rate (HR) calculated as $0.8 \cdot (220 - \text{age})$. Wall motion was recorded at the beginning of the SE and at peak effort, and reported using a conventional 16-segment model.²⁵ An ischemic response (i.e., positive SE test) was defined as worsening LV wall motion during exercise testing in comparison to the resting condition.²⁵

2.4 | Coronary angiography

Coronary angiography was performed by the Judkins' technique.²⁶ Stenosis was considered hemodynamically significant if there was a $\geq 50\%$ reduction in luminal diameter. In order to assess the severity of CAD, the Syntax score was calculated.²⁷ A Syntax score ≥ 1 was used to define the presence of atherosclerosis.

2.5 | Computed tomographic coronary angiography

Patients received nitroglycerin 0.8 mg sublingually and metoprolol targeting a HR of ≤ 65 bpm before image acquisition. In order to calculate the time interval between intravenous contrast (Visipaque 320, GE Healthcare; Milwaukee, WI) infusion and image acquisition, a bolus tracking technique was used. A triphasic protocol was used for final image acquisition (100% contrast, 40/60% contrast/saline, and 40 cc saline). The infusion rate (5–6 cc/s) and contrast volume were individualized according to the patient's body habitus and scan time. GE high-definition

CT (VCL Lightspeed 64 MD, GE) was used to acquire retrospective ECG-gated data sets with the width $64 \text{ mm} \times 0.625 \text{ mm}$ slice collimation and a gantry rotation of 350 ms ($\text{mA} = 300\text{--}800$, $\text{kV} = 120$). Pitch (0.16–0.24) was individualized to the patient's HR. The CTCA data sets were reconstructed with an increment of 0.4 mm using the cardiac phase with the least cardiac motion. Images were interpreted by two radiologists blinded to all clinical data. The Coronary calcium accumulation - Agatstone score (AS) was determined according to established guidelines.²⁸ An AS >300 was used to define the presence of atherosclerosis.

2.6 | Carotid ultrasound

Carotid ultrasound was performed by an experienced ultrasonographer who was blinded to the clinical data, using ACUSON Antares System (Siemens AG, Munich, Germany) equipped with a 4–13 MHz linear array transducer, according to established guidelines.^{29,30} Carotid intima media thickness (CIMT) was measured after the subject was placed in the supine position. The CIMT was defined as the distance between edges of the lumen-intima and the media-adventitia echoes, in a plaque-free section. CIMT was measured bilaterally, at the levels of common carotid, carotid bifurcation and internal carotid artery. Mean values were calculated for all segments. According to the results of ARIC study, subclinical atherosclerosis was considered present if CIMT was higher than 0.9 mm.^{31,32}

2.7 | Blood analysis

C-reactive protein (CRP) was determined by particle enhanced immunoturbidimetric assay (Tina-quant CRP-latex; Roche Diagnostic Corporation, Indianapolis, IN). The reference range for this assay is less than 5 mg/L.

2.8 | Scoring

The H₂FPEF score was calculated for each patient. The six variables that constitute the H₂FPEF score are: (a) BMI >30 kg/m² (2 points); (b) use of ≥ 2 antihypertensive medications (1 point); (c) history of atrial fibrillation (3 points); (d) PASP >35 mm Hg (1 point); (e) age > 60 years (1 point); and (f) $E/e' > 9$ (1 point).⁹

2.9 | Statistical analysis

Continuous data are expressed as mean and standard deviation while categorical data are expressed as percentages. In order to apply parametric statistics, analysis of distribution was performed by the Kolmogorov–Smirnov test. The differences between the groups stratified according to presence of atherosclerosis were assessed by the Student's t test for independent samples. The Mann–Whitney test was used for nonparametric variables. Correlations between variables

	Total	Positive	Negative
SE, n (%)	203/203 (100.0%)	34 (16.7%)	169 (83.3%)
Coronary angiography, n (%)	34/203 (16.7%)	18 (52.9%)	16 (47.1%)
CTCA, n (%)	203/203 (100%)	40 (19.7%)	163 (80.3%)
CIMT, n (%)	203/203 (100%)	139 (68.5%)	64 (31.5%)
Atherosclerosis, n (%)	203/203 (100%)	150 (73.9%)	53 (26.1%)

Note: Positive coronarography was considered Syntax score ≥ 1 ; positive CTCA AS >300 , positive CIMT was considered CIMT >0.9 mm and positive atherosclerosis AS >300 or IMT >0.9 mm or Syntax score ≥ 1 .

Abbreviations: AS, Agatstone score; IMT, Intima-media thickness; SE, stress echocardiography.

TABLE 1 Results of stress echocardiography, coronary angiography, computer tomographic coronary angiography, and carotid ultrasound

TABLE 2 Echocardiographic characteristics of study patients

Mean \pm SD	Positive SE (n = 34)	Negative SE (n = 169)	p value	Documented atherosclerosis (n = 149)	No documented atherosclerosis (n = 54)	p value
EF, %	62.3 \pm 9.4	67.2 \pm 6.4	<.001***	66.1 \pm 7.0	67.0 \pm 7.7	.435
LVDd, mm	4.8 \pm 0.7	4.8 \pm 0.5	.972	4.8 \pm 0.5	4.9 \pm 0.5	.630
RVDd, mm	2.1 \pm 0.4	2.0 \pm 0.4	.033*	2.0 \pm 0.4	1.9 \pm 0.4	.033*
LAV, ml	35.8 \pm 20.4	30.2 \pm 11.0	.023*	32.8 \pm 13.7	26.6 \pm 10.4	.001**
LAV index, ml/m ²	20.2 \pm 11.0	16.6 \pm 5.6	.050*	18.2 \pm 7.2	14.5 \pm 5.2	<.001***
VCI, mm	1.3 \pm 0.4	1.3 \pm 0.4	.906	1.3 \pm 0.4	1.3 \pm 0.3	.981
E/A rest	0.8 \pm 0.3	0.9 \pm 0.3	.290	0.9 \pm 0.3	1.0 \pm 0.4	.025*
E/A peak	1.0 \pm 0.4	1.2 \pm 1.6	.425	1.0 \pm 0.4	1.7 \pm 2.6	.003**
E/e' rest	10.4 \pm 4.9	8.4 \pm 2.6	.001**	9.1 \pm 3.3	7.8 \pm 2.6	.015**
E/e' peak	9.6 \pm 4.4	8.8 \pm 3.1	.229	9.2 \pm 3.3	8.0 \pm 3.2	.028*
PASP rest, mm Hg	39.5 \pm 12.6	29.66 \pm 6.4	<.001***	32.1 \pm 9.2	29.7 \pm 7.7	.167
PASP peak, mmHg	46.1 \pm 17.7	34.7 \pm 9.1	<.001***	38.2 \pm 12.4	32.8 \pm 9.9	.015*
TAPSE rest, mm	2.2 \pm 0.4	2.3 \pm 0.4	.025*	2.3 \pm 0.4	2.3 \pm 0.3	.603
TAPSE peak, mm	2.6 \pm 0.4	2.8 \pm 0.4	.005**	2.8 \pm 0.4	2.8 \pm 0.4	.867
TAPSE/PASP rest, mm/mm Hg	0.59 \pm 0.20	0.83 \pm 0.24	<.001***	0.76 \pm 0.22	0.88 \pm 0.31	.013*
TAPSE/PASP peak, mm/mm Hg	0.67 \pm 0.38	0.87 \pm 0.27	.002**	0.79 \pm 0.30	0.94 \pm 0.29	.011*

Note: Documented atherosclerosis considered Agatstone score > 300 or IMT > 0.9 mm or Syntax score ≥ 1 .

Abbreviations: A, late diastolic filling velocity of the left ventricle; e', average of septal and lateral early left ventricular diastolic filling velocity measured by tissue Doppler; E, early diastolic filling velocity of the left ventricle; EF, ejection fraction; LAV, left atrial volume; LVDd, left ventricular end-diastolic diameter; PASP, systolic pressure in pulmonary artery; RVDd, right ventricular end-diastolic diameter; TAPSE, tricuspid annular plain systolic excursion; VCI, diameter of vena cava inferior.

* $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

were performed by Pearson's correlation test and the Spearman's rank correlation test. Binary logistic regression analysis was performed to identify the best model to predict the probability of atherosclerosis. For the multivariate regression we used a forward conditional model with stepwise entry and removal criteria set at 0.05 and 0.10, respectively. Maximal iterations were set at 20. Hierarchical models were defined considering statistical significance and clinical relevance of independent variables, taking into consideration principal effects and second level interactions in each model. Measures of interest for predictive ability were compared using area under the receiver operating characteristic (ROC) curve. Two-by-two tables were built to estimate

sensitivity (Sn), specificity (Sp), predictive values and 95% confidence intervals. Statistical tests were considered significant when a p-value was <0.05 for all tests. The SPSS software package (SPSS version 27.0, SPSS Inc., Armonk, NY) was used for all analyses.

3 | RESULTS

For 203 patients with SCTD enrolled, the mean age was 57.7 \pm 11.2 years and 87.7% were female. The average time since diagnosis was 8.6 \pm 7.9 years. Of the 203 subjects, 52 (25.6%) were

diagnosed with RA, 51 (25.1%) with SLE, 50 (24.6%) with SSc and 50 (24.6%) with SS. Twenty eight of the subjects were only receiving symptomatic therapy (13.8%), 65 (32.0%) were receiving monotherapy (i.e. immunosuppressive drugs or biological therapy) and 110 (54.2%) were receiving combined specific therapy. The clinical data and the prevalence of CVDRF are given in Table S1.

All patients underwent SE testing; 34/203 (16.7%) tests were described as positive in terms of the presence of myocardial ischemia. All subjects with a positive SE test underwent catheterization and, of those catheterized, 18/34 (52.9%) had significant lesions in the coronary arteries detected (Syntax score ≥ 1). Average Syntax score of all catheterized subjects was 8.3 ± 14.6 . Of 18 patients with a Syntax score ≥ 1 , five patients underwent a further revascularization procedure (two for percutaneous coronary intervention and three for coronary artery by pass graft).

CTCA and CIMT measurements were performed in all subjects; 40/203 (19.7%) had AS >300 and 139/203 (68.5%) had CIMT >0.9 mm. Average AS was 286.3 ± 696.3 and average CIMT was 1.2 ± 0.6 mm.

Subjects who demonstrated a AS >300 , CIMT >0.9 mm or Syntax score ≥ 1 were arbitrarily considered to have documented atherosclerosis, as given in Table 1.

Echocardiographic data of patients with and without a positive SE test, as well as the presence or absence of atherosclerosis, are given in Table 2. RVDd, LAV, LAV index, resting E/e' and peak PASP were higher, while TAPSE/PASP at rest and peak were lower in subjects with positive SE and documented atherosclerosis. Patients with a positive SE test also had a lower LVEF and resting and peak TAPSE, whereas resting PASP was higher than in patients with a negative SE test. Patients with documented atherosclerosis had a lower resting and peak E/A and higher peak E/e' compared to patients with no documented atherosclerosis.

All patients had a LVEF $\geq 50\%$, except three patients that had a LVEF of 45%, which were excluded from further analysis. Mean H₂FPEF score for patients with a LVEF $\geq 50\%$ was 1.8 ± 1.4 . H₂FPEF score significantly correlated with the presence of atherosclerosis and SE positivity ($r = 0.3, 0.2; p < .001, p = .005$, respectively). H₂FPEF score significantly correlated with TAPSE/PASP at rest and peak ($r = -0.3, -0.2; p = .001, .013$, respectively).

On binary logistic regression analysis, CVDRF category, number of CVDRFs, VCI diameter, CRP and duration of illness were not significant predictors of atherosclerosis presence or a positive SE test. Significant predictors of both atherosclerosis presence and a positive SE test were RVDd, E/e' rest, LAV, LAV index, TAPSE/PASP at rest and peak, and H₂FPEF score as given in Table 3 (A,B). LVEF was not a significant predictor of atherosclerosis presence, but significantly predicted a positive SE test. Peak E/e' significantly predicted atherosclerosis presence but did not have predictive value for a positive SE test. In a multivariate model, including all significant univariate predictors, only H₂FPEF score remained in the regression for the prediction of atherosclerosis presence ($\chi^2 = 19.3$, HR 2.6, CI 1.5–4.3, $p < .001$). When H₂FPEF score was removed from the analysis, the only predictor that remained in the equation was peak TAPSE/PASP ($\chi^2 = 4.1$,

TABLE 3 Univariate and multivariate binary logistic regression analysis for key clinical and echocardiographic variables in the prediction of (A) atherosclerosis presence and (B) positivity of SE

(A)	χ^2	Hazard ratio	95% CI	p value
Univariate analysis				
RVDd	4.2	2.5	1.0–5.9	.046*
LAV index	14.2	1.1	1.0–1.2	.001**
LAV	9.9	1.0	1.0–1.1	.035*
E/e'a rest	7.0	1.2	1.0–1.3	.015*
E/e'a peak	5.3	1.1	1.0–1.3	.031*
TAPSE/PASP rest	5.9	0.2	0.1–0.7	.017*
TAPSE/PASP peak	6.0	0.2	0.1–0.8	.016*
H ₂ FPEF score	10.7	1.5	1.2–2.0	.002**
Multivariate analysis				
H ₂ FPEF score	19.3	2.6	1.5–4.3	<.001***
(B)	χ^2	Hazard ratio	95% CI	p value
Univariate analysis				
EF	12.4	0.9	0.9–1.0	.001**
RVDd	4.4	2.7	1.1–6.9	.036*
LAV index	6.6	1.1	1.0–1.1	.010*
LAV	4.6	1.0	1.0–1.1	.030*
E/e'a rest	9.9	1.2	1.1–1.3	.003**
TAPSE/PASP rest	27.6	0.01	0.01–0.03	<.001***
TAPSE/PASP peak	12.6	0.04	0.01–0.29	.002**
H ₂ FPEF score	6.1	1.4	1.1–1.9	.013*
Multivariate analysis				
TAPSE/PASP rest	10.4	0.01	0.01–0.22	.004**

Note: Documented atherosclerosis considered Agatstone score > 300 or IMT > 0.9 mm or Syntax score ≥ 1 .

Abbreviations: E, early diastolic filling velocity of the left ventricle; e'a, average of septal and lateral early left ventricular diastolic filling velocity measured by tissue Doppler; EF, ejection fraction; H₂FPEF score, heart failure preserved ejection fraction score; LAV, left atrial volume; PASP, systolic pressure in pulmonary artery; RVDd, right ventricular end-diastolic diameter; TAPSE, tricuspid annular plain systolic excursion.


* $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

HR 0.2, CI 0.1–1.0, $p = .049$). In the multivariate model, the only predictor that remained in the regression for the prediction of SE positivity was resting TAPSE/PASP ($\chi^2 = 10.4$, HR 0.01, CI 0.01–0.22, $p = .004$).

In order to detect parameters to distinguish between those patients with and without atherosclerosis, ROC analysis was additionally used. The best predictive ability was shown for the H₂FPEF score (area under ROC curve 0.67, SE = 0.05, $p < .001$). The optimal threshold value for identifying patients with atherosclerosis was a H₂FPEF score ≥ 2 , which produced a Sn and Sp of 60.4% and 69.4%, respectively, as shown in Figure 1. Predictive value was also shown for peak TAPSE/PASP (area under ROC curve 0.35, SE = 0.05, $p = .004$), as shown at Figure S1.

On ROC analysis, H₂FPEF score was also shown to have a predictive value for identifying patients with positive and negative SE test


ROC Curve demonstrating predictive ability of H₂FPEF score ≥ 2 for identifying patients with atherosclerosis presence



Diagonal segments are produced by ties.

FIGURE 1 Receiver operating characteristic (ROC) curve demonstrating predictive ability of H₂FPEF score ≥ 2 for identifying patients with atherosclerosis presence

ROC Curve demonstrating predictive ability of H₂FPEF score ≥ 2 for identifying patients with positive SE test



Diagonal segments are produced by ties.

FIGURE 2 Receiver operating characteristic (ROC) curve demonstrating predictive ability of H₂FPEF score ≥ 2 for identifying patients with positive SE test

(area under ROC curve 0.67, SE = 0.05, $p = .006$). The optimal threshold value for identifying patients with a positive SE test was a H₂FPEF score ≥ 2 , which produced a Sn and Sp of 76.0% and 48.7%, respectively, as shown in Figure 2. A predictive value in distinguishing between a positive and negative SE test was also shown for resting TAPSE/PASP (area under ROC curve 0.21, SE = 0.05, $p < .001$), as shown at Figure S2.

4 | DISCUSSION

The present findings demonstrate that more than two thirds of patients with SCTD had occult atherosclerosis. Patients with atherosclerosis demonstrate a worsened echocardiographic phenotype as indicated by a larger RV and LA, higher LV diastolic filling pressures at rest and during exercise, as well as a lower resting and peak TAPSE/PASP, suggesting worse RV-PV coupling. The recently developed H₂FPEF score, a powerful tool in predicting HFpEF presence,⁹ outperformed all other measures assessed in the present study, including the ESC CVD risk categorization, in the prediction of atherosclerosis presence. A high predictive value for atherosclerosis presence and development of myocardial ischemia in patients diagnosed with SCTD was also demonstrated for rest and peak TAPSE/PASP, and they both significantly correlated with H₂FPEF score.

Accumulating evidence points to the existence of increased CVD risk in patients diagnosed with SCTD in comparison to the general population, particularly in patients with RA, whose risk is comparable with diabetes mellitus.³²⁻³⁴ Studies show that the risk of myocardial infarction is approximately 70% higher in these patients than in general population.³⁵ Early recognition of CVD risk in SCTD patients is of a great clinical importance, as that would prevent future adverse events and poor survival. There is a need to find an easy method, feasible not only for experts in cardiology and internal medicine, but every other physician involved in care of patients diagnosed with SCTD. In addition to standard CVDRFs which are emphasized in SCTD, such as physical inactivity due to functional disability, common concomitant hypothyroidism, diabetes mellitus, hyperlipidemia, chronic kidney disease and hypertension, there are novel risk factors playing a role in this condition, such as inflammation and applied therapy.¹ Drugs with powerful suppression of inflammation may slow down progression of atherosclerosis.¹ There is accumulating evidence that decreasing the inflammatory burden, by biologic therapy, RA patients translates into a lower CVD risk.¹ Besides RA, no other SCTD is currently incorporated into any widely accepted CVD risk calculators.² This is not appropriate approach, as accelerated atherosclerosis and heart failure coexist in all distinct phenotypes of SCTD.^{5,32,34,36} The mechanisms that contribute to accelerated atherosclerosis are still incompletely understood. Chronic systemic inflammation and autoimmunity interfere in a number of metabolic processes, influencing liver function, skeletal muscles, and fat tissue, generated a proatherogenic condition.^{1,4} The proinflammatory cytokines, such as tumor necrosis factor (TNF)- α and interleukin (IL)-6, lead to endothelial dysfunction and activation, primarily in patients with RA.¹ Enhanced expression of

adhesion molecules (such as vascular cell adhesion protein 1, or VCAM-1) on the endothelial and smooth muscle cell surfaces is associated with cardiovascular disorders in RA and SLE.⁴ In SLE patients CVD are generally independent of traditional risk factors and SLE itself has been shown to be a substantial risk factor for the development of atherosclerosis.^{4,35} In addition to the role of inflammation, patients with SLE have antinuclear antibodies which might have a pathophysiological role.⁴ The underlying mechanisms for atherosclerosis in patients with SSc involve endothelial injury and reduced oxygen transport to tissues. SSc (both limited and diffuse disease) is also associated with increased stiffness of the vasculature.⁷ Although RA exhibited the highest CVD risk, the one is only slightly lower in SSc, SLE, and SS.^{1,33,36} This observation was encouraging to examine all these SCTD in the current study. Although highly recommended to determine,^{1,2} SCORE CVD risk evaluation in patients with SCTD underestimates real CVD risk.¹ Even with a deeper diagnostic approach suggested by guidelines, including screening for asymptomatic atherosclerotic plaques through carotid ultrasound, CVD risk estimation is still based on expert opinion.^{1,2} Previous evidence indicates SCTD leads to myocardial inflammation, abnormalities of coronary microcirculation, diastolic dysfunction, LA enlargement, and finally HFpEF.⁷ Interestingly, women have greater risk and suffer greater cardiac consequences from these systemic inflammatory and metabolic disorders.⁵ Coronary artery calcifications, a marker of coronary atherosclerosis, are shown to stratify risk of HFpEF beyond traditional risk factors in women.²⁹ Accordingly, a new marker was recently identified, an inflammatory-metabolic phenotype of HFpEF, characterized by biomarkers of inflammation, microvascular endothelial dysfunction, normal-to-mildly increased left ventricular volumes and systolic blood pressures, and altered activity of adipocyte-associated inflammatory mediators.⁵ This HFpEF phenotype may express independent of large vessel coronary artery disease.⁵ The proposed underlying pathophysiology for this condition is an inflammatory response to an ectopic accumulation of dysfunctional lipids, in the epicardium or small coronary vessels, leading to fibrosis of the adjacent myocardium, ventricular and atrial, with consequent impairment of diastolic function and atrial fibrillation.^{5,30,31} This sequence could explain the link between accelerated atherosclerosis in SCTD and HFpEF development.³¹ In support, our study demonstrated larger LA, and higher LV diastolic filling pressures at rest and during effort in SCTD subjects with positive SE and documented atherosclerosis, but also the impact on RV function and worsening RV-PV coupling, which is an increasingly important feature in HFpEF.³² Previous studies have demonstrated that right heart function is a crucial determinant of outcome in HF patients regardless of LV function or predominance of systolic or diastolic HF.³³ In atherosclerotic patients, abnormalities in PASP and PVR are observed with a direct link to incident HFpEF and it is proposed that impairments in PV function may precede clinical HFpEF.³⁴ Accordingly, the link between TAPSE/PASP as a measure of RV-PV coupling and RV function was shown to provide a comprehensive tool for risk stratification in HFpEF.³² In our study, the TAPSE/PASP response demonstrated a high predictive value for atherosclerosis presence and positive SE test, outperforming other LA and LV parameters,

suggesting the importance of RV and pulmonary circulatory dysfunction in atherosclerotic patients with SCTD. The significant correlation of TAPSE/PASP with the H₂FPEF supports the link of RV-PV uncoupling and HFpEF, which is already very well known.³⁵

Nonetheless, a H₂FPEF score was superior to TAPSE/PASP both at rest and peak exercise in the prediction of atherosclerosis presence, supporting its' comprehensive nature in assessing clinical status. Considering the potential presence of both HFpEF and atherosclerosis in SCTD patients, the strong predictive value of the H₂FPEF score is not surprising, as all components of the score are in a way a reflection of underlying pathophysiology. Some previous studies have demonstrated that a high H₂FPEF score may be associated with a high SYNTAX score and may be used to estimate the extent and complexity of coronary artery disease.³⁶ Simplicity of the determination and calculation of the H₂FPEF score is of a particular value from a clinical perspective, which may help planning further diagnostic procedures in the evaluation of SCTD patients with suspected atherosclerosis.

5 | LIMITATIONS

A limitation of this study is the lack of invasive hemodynamic evaluation for HFpEF presence. Sub analyses on age and gender were not performed due to the limited numbers in specific subsets of patients, which should be addressed in future studies. Moreover, to define the presence of atherosclerosis, the cut off values were arbitrarily chosen. While CIMT >0.9 mm is commonly used and easily understood by most clinicians³⁷, the impact of age and sex cannot be neglected.³⁸ Furthermore, CIMT measurements were usually performed at the common carotid artery, however previous studies differed according to measurement side (left side versus right side), measurement wall (far wall versus near wall) and method of combination of single measurements (mean versus mean-maximum).^{39,40} The use of different ultrasound machines with varying transducer frequencies may also be impactful.^{39,40} Syntax score ≥ 1 is another cut off determinant that could be understood as too low, however, the intention was to identify any presence of atherosclerosis, regardless of its significance. The cut off for AS >300 was chosen as it was shown previously to be associated to markedly increased CVD risk, however that risk was observed in patients with AS >100 as well.⁴¹ Another limitation of the current study is low H₂FPEF score observed in study population. Future studies with more severe patients and higher score are warranted.

6 | CONCLUSIONS

The H₂PHEF score has strong predictive value for atherosclerosis presence in patients diagnosed with SCTD. The same was shown for TAPSE/PASP measured at rest and during peak exercise, novel unfavorable markers of RV-PV uncoupling and RV dysfunction, which correlate with the H₂PHEF score. Present findings indicate the need to systematically calculate H₂PHEF score in patients with SCTD in order to help reveal occult atherosclerosis.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

DATA AVAILABILITY STATEMENT

Research data are not shared.

ORCID

Dejana Popovic  <https://orcid.org/0000-0002-6647-5872>

REFERENCES

- Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis*. 2017;76(1):17-28.
- Authors/Task Force Members, Piepoli MF, Hoes AW, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). *Atherosclerosis*. 2016;252:207-274.
- D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation*. 2008;117:743-753.
- Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R. Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. *Expert Rev Clin Immunol*. 2007;3(4):531-541.
- Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. *Eur J Heart Fail*. 2020;22(9):1551-1567.
- Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. *Int J Rheum Dis*. 2017;20(1):5-24.
- Bourji KI, Kelemen BW, Mathai SC, et al. Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. *Pulm Circ*. 2017;7(2):409-420.
- DuBrock HM, Redfield MM, Abou Ezzeddine OF. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. *PLoS One*. 2018;13:e0201836.
- Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation*. 2018;138(9):861-870.
- Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*. 1988;31(3):315-324.
- Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. *Ann Rheum Dis*. 2010;69(9):1580-1588.
- Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1982;25(11):1271-1277.
- Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64(8):2677-2686.
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. *Arthritis Rheum*. 1980;23(5):581-590.
- van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheum*. 2013;65(11):2737-2747.
- Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. *Ann Rheum Dis*. 2002;61(6):554-558.
- Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's international collaborative clinical Alliance cohort. *Arthritis Care Res*. 2012;64(4):475-487.
- Andersen MJ, Nishimura RA, Borlaug BA. The hemodynamic basis of exercise intolerance in tricuspid regurgitation. *Circ Heart Fail*. 2014;7:911-917.
- Opatowsky AR, Ojeda J, Rogers F, et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. *Circ Cardiovasc Imaging*. 2012;5:765-775.
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16(3):233-270.
- Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.
- Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23:685-713.
- Guazzi M, Bandera F, Pelissero G, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. *Am J Physiol Heart Circ Physiol*. 2013;305:1373-1381.
- Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation*. 2013;128:873-934.
- Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. *J Am Soc Echocardiogr*. 2007;20(9):1021-1041.
- Scanlon PJ, Faxon DP, Audet AM, et al. Developed in collaboration with the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol*. 1999;33(6):1756-1824.
- Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention*. 2005;1:219-227.
- Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation appropriate use criteria task force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol*. 2010;56:1864-1894.
- Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular

- disease risk: a consensus statement from the American Society of Echocardiography carotid intima-media thickness task force. Endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr*. 2008;21(2):93-111.
30. Saba L, Jamthikar A, Gupta D, et al. Global perspective on carotid intima-media thickness and plaque: should the current measurement guidelines be revisited? *Int Angiol*. 2019;38(6):451-465.
 31. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The atherosclerosis risk in communities (ARIC) study. *Stroke*. 1995;26(3):386-391.
 32. Ristić GG, Lepić T, Glisić B, et al. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. *Rheumatology (Oxford)*. 2010;49(6):1076-1081.
 33. Van Halm VP, Peters MJL, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. *Ann Rheum Dis*. 2009;68:1395-1400.
 34. Ristić GG, Subota V, Lepić T, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis and low cardiovascular risk: the role of von Willebrand factor activity. *PLoS One*. 2015;10(8):30462.
 35. Alenghat FJ. The prevalence of atherosclerosis in those with inflammatory connective tissue disease by race, age, and traditional risk factors. *Sci Rep*. 2016;6:20303.
 36. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. *Ann Rheum Dis*. 2011;70:929-934.
 37. Sharma K, Al Rifai M, Ahmed HM, et al. Usefulness of coronary artery calcium to predict heart failure with preserved ejection fraction in men versus women (from the multi-ethnic study of atherosclerosis). *Am J Cardiol*. 2017;120(10):1847-1853.
 38. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. *J Am Coll Cardiol*. 2018;71:2360-2372.
 39. Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. *JACC Heart Fail*. 2020;8(8):640-653.
 40. Santas E, De la Espriella R, Chorro FJ, et al. Right ventricular dysfunction staging system for mortality risk stratification in heart failure with preserved ejection fraction. *J Clin Med*. 2020;9(3):831.
 41. Popovic D, Arena R, Guazzi M. A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction. *Eur J Heart Fail*. 2018;20(7):1115-1124.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Vasilev V, Popovic D, Ristic GG, Arena R, Radunovic G, Ristic A. H₂FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease. *Clin Cardiol*. 2021;1-9. <https://doi.org/10.1002/clc.23621>